Modernizing Medical Retina: Review of the Pipeline

1-8 of 8

Diabetic Eye Disease Pipeline Therapies Part 2: High-dose Aflibercept & Gene Therapy
Diabetic Eye Disease Pipeline Therapies Part 2: High-dose Aflibercept & Gene Therapy
CME/CE Broadcast Replay
Diabetic Eye Disease Pipeline Therapies Part 2: High-dose Aflibercept & Gene Therapy
Christina Y. Weng, MD, MBA; Glenn Yiu, MD, PhD
0.50 credits
- Christina Y. Weng, MD, MBA
- Glenn Yiu, MD, PhD
0.50 credits
Diabetic Eye Disease Pipeline Therapies Part 3: Brolucizumab & PDS
Diabetic Eye Disease Pipeline Therapies Part 3: Brolucizumab & PDS
CME/CE Broadcast Replay
Diabetic Eye Disease Pipeline Therapies Part 3: Brolucizumab & PDS
Sophie J. Bakri, MD; Christina Y. Weng, MD, MBA
0.50 credits
- Sophie J. Bakri, MD
- Christina Y. Weng, MD, MBA
0.50 credits
How Treatments for DR/DME are Modernizing Medical Retina
How Treatments for DR/DME are Modernizing Medical Retina
CME/CE
How Treatments for DR/DME are Modernizing Medical Retina
Sophie J. Bakri, MD; Christina Y. Weng, MD, MBA
1.00 credit
- Sophie J. Bakri, MD
- Christina Y. Weng, MD, MBA
- David A. Eichenbaum, MD, FAAO
- Glenn Yiu, MD, PhD
1.00 credit
Diabetic Eye Disease Pipeline Therapies Part 1: Faricimab, KSI-301, and OPT-302
Diabetic Eye Disease Pipeline Therapies Part 1: Faricimab, KSI-301, and OPT-302
CME/CE Broadcast Replay
Diabetic Eye Disease Pipeline Therapies Part 1: Faricimab, KSI-301, and OPT-302
Christina Y. Weng, MD, MBA; David A. Eichenbaum, MD, FAAO
0.50 credits
- Christina Y. Weng, MD, MBA
- David A. Eichenbaum, MD, FAAO
0.50 credits
Modernizing Medical Retina: Review of the Pipeline
Modernizing Medical Retina: Review of the Pipeline
CME/CE
Modernizing Medical Retina: Review of the Pipeline
Diana V. Do, MD; Christina Y. Weng, MD, MBA
1.00 credit
- Diana V. Do, MD
- Christina Y. Weng, MD, MBA
- Peter A. Campochiaro, MD
- Basil K. Williams Jr, MD
1.00 credit
Wet AMD Pipeline Therapies Part 3: KSI-301 and GB-102
Wet AMD Pipeline Therapies Part 3: KSI-301 and GB-102
CME/CE Broadcast Replay
Wet AMD Pipeline Therapies Part 3: KSI-301 and GB-102
Christina Y. Weng, MD, MBA; Basil K. Williams Jr, MD
0.50 credits
- Christina Y. Weng, MD, MBA
- Basil K. Williams Jr, MD
0.50 credits
Wet AMD Pipeline Therapies Part 2: PDS and RGX-314
Wet AMD Pipeline Therapies Part 2: PDS and RGX-314
CME/CE Broadcast Replay
Wet AMD Pipeline Therapies Part 2: PDS and RGX-314
Christina Y. Weng, MD, MBA; Peter A. Campochiaro, MD
0.75 credits
- Christina Y. Weng, MD, MBA
- Peter A. Campochiaro, MD
0.75 credits
Wet AMD: Pipeline Therapies Part 1 - Faricimab and OPT-302
Wet AMD: Pipeline Therapies Part 1 - Faricimab and OPT-302
CME/CE Broadcast Replay
Wet AMD: Pipeline Therapies Part 1 - Faricimab and OPT-302
Diana V. Do, MD; Christina Y. Weng, MD, MBA
0.50 credits
- Diana V. Do, MD
- Christina Y. Weng, MD, MBA
0.50 credits

1-8 of 8

Title